CIPLA's weekly performance was disappointing, with a return of -5.89% and a Sharpe Ratio of -1.51, indicating poor risk-adjusted returns. The stock's volatility was relatively moderate at 15.84%, but still contributed to its underperformance compared to peers. Specifically, CIPLA underperformed SUNPHARMA and GRASIM, but outperformed DIVISLAB. Overall, the stock was relatively risky this week, with a Max Drawdown of -5.89%.

[Volatility: 15.84%]